

117TH CONGRESS
1ST SESSION

H. R. 6047

To direct the Secretary of Health and Human Services to submit to Congress a report on COVID–19 natural immunity, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

NOVEMBER 18, 2021

Mr. ROY (for himself, Mr. MASSIE, Mr. PERRY, Mr. ROSENDALE, Mrs. BOEBERT, Ms. STEFANIK, Mr. WEBER of Texas, and Mr. GOHMERT) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To direct the Secretary of Health and Human Services to submit to Congress a report on COVID–19 natural immunity, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Natural Immunity
5 Transparency Act”.

6 **SEC. 2. REPORT ON COVID–19 NATURAL IMMUNITY.**

7 (a) IN GENERAL.—Not later than 30 days after the
8 date of the enactment of this Act, the Secretary of Health

1 and Human Services shall submit to Congress a report
2 that contains the following data—

3 (1) the number of individuals who recovered
4 from a COVID–19 infection, and never received a
5 COVID–19 vaccine, during the period beginning on
6 January 1, 2020, and ending on such date of enact-
7 ment, and who subsequently—

8 (A) died from a COVID–19 infection;

9 (B) were hospitalized from a COVID–19
10 infection;

11 (C) had an additional confirmed case of
12 COVID–19; or

13 (D) transmitted SARS–CoV–2 to another
14 person or persons while reinfected; and

15 (2) the number of individuals who received all
16 recommended doses of a COVID–19 vaccine during
17 the period beginning on December 14, 2020, and
18 ending on such date of enactment, and who subse-
19 quently—

20 (A) died from a COVID–19 infection;

21 (B) were hospitalized from a COVID–19
22 infection; or

23 (C) had a confirmed breakthrough case.

24 (b) DEFINITIONS.— In this section:

1 (1) BREAKTHROUGH CASE.—The term “break-
2 through case”, with respect to a case of COVID–19,
3 means the detection of SARS–CoV–2 RNA or anti-
4 gen in a respiratory specimen collected from an indi-
5 vidual at least 14 days after the date on which such
6 individual received all recommended doses of a
7 COVID–19 vaccine.

8 (2) COVID–19 VACCINE.—The term “COVID–
9 19 vaccine” means a vaccine for COVID–19 that
10 has been licensed under section 351 of the Public
11 Health Service Act (42 U.S.C. 262) or authorized
12 for emergency use under section 564 of the Federal
13 Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–
14 3).

○